Preoperative chemotherapy, radiotherapy and surgical decision-making in patients with borderline resectable and locally advanced pancreatic cancer

TF Stoop, RT Theijse, LWF Seelen… - Nature Reviews …, 2024 - nature.com
Surgical resection combined with systemic chemotherapy is the cornerstone of treatment for
patients with localized pancreatic cancer. Upfront surgery is considered suboptimal in cases …

Imaging Assessment of Pancreatic Cancer Resectability After Neoadjuvant Therapy: AJR Expert Panel Narrative Review

EV Soloff, MM Al-Hawary, TS Desser… - American Journal of …, 2022 - Am Roentgen Ray Soc
Despite important innovations in the treatment of pancreatic ductal adenocarcinoma
(PDAC), PDAC remains a disease with poor prognosis and high mortality. A key area for …

Bounding box-based 3D AI model for user-guided volumetric segmentation of pancreatic ductal adenocarcinoma on standard-of-care CTs

S Mukherjee, P Korfiatis, H Khasawneh, N Rajamohan… - Pancreatology, 2023 - Elsevier
Objectives To develop a bounding-box-based 3D convolutional neural network (CNN) for
user-guided volumetric pancreas ductal adenocarcinoma (PDA) segmentation. Methods …

Pancreatic ductal adenocarcinoma staging: a narrative review of radiologic techniques and advances

LC Chu, EK Fishman - International journal of surgery, 2024 - journals.lww.com
Radiology plays an important role in the initial diagnosis and staging of patients with
pancreatic ductal adenocarcinoma (PDAC). CT is the preferred modality over MRI due to …

Added value of digital FDG-PET/CT in disease staging and restaging in patients with resectable or borderline resectable pancreatic cancer

TL de Jong, D Koopman, CAJ van der Worp… - Surgical Oncology, 2023 - Elsevier
Background We studied the added value of digital FDG-PET/CT in disease staging and
restaging compared to the standard work-up with contrast enhanced CT (ceCT) and CA19-9 …

Overview and future perspectives on tumor-targeted positron emission tomography and fluorescence imaging of pancreatic cancer in the era of neoadjuvant therapy

MA van Dam, FA Vuijk, JA Stibbe, RD Houvast… - Cancers, 2021 - mdpi.com
Simple Summary Patients diagnosed with pancreatic cancer have a poor prognosis at time
of diagnosis, with a 5-year survival rate of merely 10%. The only treatment with curative …

Added value of 3T MRI and the MRI-halo sign in assessing resectability of locally advanced pancreatic cancer following induction chemotherapy (IMAGE-MRI) …

TF Stoop, E van Veldhuisen, LB van Rijssen… - … Archives of Surgery, 2022 - Springer
Background Restaging of locally advanced pancreatic cancer (LAPC) after induction
chemotherapy using contrast-enhanced computed tomography (CE-CT) imaging is …

Application of magnetic resonance imaging in neoadjuvant treatment of pancreatic ductal adenocarcinoma

C Qu, P Zeng, H Wang, C Yuan… - Journal of Magnetic …, 2022 - Wiley Online Library
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignant tumors of the
human digestive system. Due to its insidious onset, many patients have already lost the …

Postoperative surveillance of pancreatic ductal adenocarcinoma (PDAC) recurrence: practice pattern on standardized imaging and reporting from the society of …

LC Chu, ZJ Wang, A Kambadakone, EM Hecht… - Abdominal …, 2023 - Springer
Purpose Surgical resection is the only potential curative treatment for patients with
pancreatic ductal adenocarcinoma (PDAC), but unfortunately most patients recur within 5 …

Prognostic Significance of Biologic Factors in Patients with a Modest Radiologic Response to Neoadjuvant Treatment for Resectable and Borderline Resectable …

S Miyahara, H Takahashi, H Akita, K Sasaki… - Annals of Surgical …, 2024 - Springer
Background Appropriate re-evaluation after neoadjuvant treatment (NAT) is important for
optimal treatment selection. Nonetheless, determining the operative eligibility of patients …